Galactan biosynthesis in Mycobacterium tuberculosis - Identification of a bifunctional UDP-galactofuranosyltransferase

The cell wall of Mycobacterium tuberculosis and related genera is unique am ong prokaryotes, consisting of a covalently bound complex of mycolic acids, D-arabinan and D-galactan, which is linked to peptidoglycan via a special linkage unit consisting of Rhap-(1 -->3)-GlcNAc-P. Information concerning t he biosynthesis of this entire polymer is now emerging with the promise of new drug targets against tuberculosis. Accordingly, we have developed a gal actosyltransferase assay that utilizes the disaccharide neoglycolipid accep ters beta -D-Galf-(1 -->5)-beta -Galf-O-C-10:1 and beta -D-Galf-(1 -->6)-be ta -D-Galf-O-C-10:1, with UDP-Gal in conjunction with isolated membranes. C hemical analysis of the subsequent reaction products established that the e nzymatically synthesized products contained both beta -D-Galf linkages ((1 -->5) and (1 -->6)) found within the mycobacterial cell, as well as in an a lternating (1 -->5) and (1 -->6) fashion consistent with the established st ructure of the cell wall. Furthermore, through a detailed examination of th e M. tuberculosis genome, we have shown that the gene product of Rv3808c, n ow termed glfT is a novel UDP-galactofuranosyltransferase, This enzyme poss esses dual functionality in per forming both (1 -->5) and (1 -->6) galactof uranosyltransferase reactions with the above neoglycolipid accepters, using membranes isolated from the heterologous host Escherichia coli expressing Rv3808c, Thus, at a biochemical and genetic level, the polymerization of th e galactan region of the mycolyl-arabinogalactan complex has been defined, allowing the possibility of further studies toward substrate recognition an d catalysis and assay development. Ultimately, this may also lead to a more rational approach to drug design to be explored in the context of mycobact erial infections.